MiNK Therapeutics

INKT51

Penny Stock

$0.75arrow_drop_down3.37%-$0.02

Penny Stock

INKT51

$0.75

arrow_drop_down3.37%-$0.02

Penny Stock

Performance History

Key Stats
Open	$0.77
Prev. Close	$0.75
EPS	-0.48
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$29.81M
PE Ratio	-

	LOW	HIGH
Day Range	0.70	0.82
52 Week Range	0.68	1.90

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.48

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About MiNK Therapeutics (INKT)

MiNK Therapeutics, Inc. (INKT) is a pharmaceutical company focused on developing innovative therapies for various diseases. The company's stock price history has shown fluctuation over the years, with ups and downs reflecting market conditions and investor sentiment. INKT has been listed on the stock exchange under the ticker symbol INKT. Investors can track the stock's performance through real-time quotes and charts.

Recent news regarding MiNK Therapeutics, Inc. (INKT) includes announcements about the company's research advancements, clinical trials, partnerships, and regulatory updates. These news releases provide valuable insights into the progress of INKT and its potential impact on the healthcare industry. Investors should stay updated with the latest news to make informed decisions about their investment in MiNK Therapeutics.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Jennifer S. Buell Ph.D.
Headquarters: New York
Employees: 37
Exchange: NASDAQ

Keep an eye on MiNK Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of MiNK Therapeutics (INKT)?

MiNK Therapeutics (INKT) has a market capitalization of $29.81M. The average daily trading volume is 0.74, indicating the stock's liquidity and investor engagement.

help

What is MiNK Therapeutics's (INKT) price per share?

The current price per share for MiNK Therapeutics (INKT) is $0.75. The stock has seen a price change of -$0.03 recently, indicating a -3.37% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for MiNK Therapeutics (INKT)?

For MiNK Therapeutics (INKT), the 52-week high is $1.9, which is 151.99% from the current price. The 52-week low is $0.68, the current price is 10.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is MiNK Therapeutics (INKT) a growth stock?

MiNK Therapeutics (INKT) has shown an average price growth of -6.65% over the past three years. It has received a score of 1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying MiNK Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is MiNK Therapeutics (INKT) stock price performance year to date (YTD)?

As of the latest data, MiNK Therapeutics (INKT) has a year-to-date price change of -30.83%. Over the past month, the stock has experienced a price change of 9.28%. Over the last three months, the change has been -6.9%. Over the past six months, the figure is -27.5%.

help

Is MiNK Therapeutics (INKT) a profitable company?

MiNK Therapeutics (INKT) has a net income of -$22.46M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$22.92M. Furthermore, the EBITDA is -$17.25M.